Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Spyre Therapeutics ( (SYRE) ) just unveiled an announcement.
Spyre Therapeutics, a clinical-stage biotech firm, is advancing its pipeline with a novel monoclonal antibody, SPY003, targeting IL-23 for treating inflammatory bowel disease (IBD). With promising preclinical results and extended half-life, SPY003 could offer a more convenient dosing schedule. The company plans to start first-in-human trials by early 2025, potentially enhancing efficacy and convenience of IBD therapies compared to current standards.
Learn more about SYRE stock on TipRanks’ Stock Analysis page.
